Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: A proton magnetic resonance spectroscopy study

Neurology

Volumn 49, Issue 2, 1997, Pages 438-444

  Ellis, C M ^a   Lemmens, G ^a   Williams, S C R ^b,c   Simmons, A ^b,c   Dawson, J ^a,c   Leigh, P N ^a   Chaudhuri, K Ray ^a,d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d University Department of Neurology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DERIVATIVE; LEVODOPA; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DEAFFERENTATION; HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN;

EID: 0030840579     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.438     Document Type: Article

References (26)

1. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
2. Lach B, Grimes D, Benoit B, Minkiewicz JA. Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol (Berl) 1992;83:352-360.
3. Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 1994;241:354-371.
4. Howe FA, Maxwell RJ, Saunders DE, Brown MM, Griffiths JR. Proton spectroscopy in vivo. Magn Reson Q 1993;9:31-59.
5. Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-210.
6. Holshouser BA, Komu M, Moller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicentre pilot study. Magn Reson Med 1995;33:589-594.
7. Chaudhuri KR, Lemmens GM, Williams SCR, et al. Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. Parkinsonism Relat Disord 1996;2:63-67.
8. Simoes F, Ribiero JA, Soares R, Pereira S, Duarte F. In vivo localized proton MR spectroscopy in the striatum of patients with Parkinson's disease [abstract]. Mov Disord 1996;11(suppl 1):178.
9. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
10. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
11. Marek KL, Seibyl JP, Sandridge B, et al. SPECT imaging with [1-123]beta-CIT demonstrates striatal dopamine transporter loss in parkinsonism [abstract]. Neurology 1994; 44(suppl 20):A352.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
13. Mathias CJ, Bannister R. Investigation of autonomie disorders. In: Bannister R, Mathias CJ, eds. Autonomic failure: a textbook of clinical disorders of the autonomie nervous system. 3rd ed. Oxford: Oxford University Press, 1992:255-290.
14. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
15. Ordidge RJ, Bendall MR, Gordon RE, Connolly A. Volume selection for in-vivo biological spectroscopy. In: Govil G, Khetrapal S, eds. Magnetic resonance in biology and medicine. New Delhi: McGraw-Hill, 1985:387-397.
16. Bottomley PA. Spatial localisation in NMR-spectroscopy in vivo. Ann NY Acad Sci 1987;508:333-348.
17. Clarke CE, Lowry M, Horsman A. Normal basal ganglia glutamate and N-acetyl-aspartate in Parkinson's disease measured by proton magnetic resonance spectroscopy [abstract]. Mov Disord 1996;11(suppl 1):103.
18. Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993;8:134-138.
19. Schwarz J, Tatsch K, Arnold G, et al. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556-561.
20. Sawle GV. Imaging the head: functional imaging. J Neurol Neurosurg Psychiatry 1995;58:132-144.
21. Arnold DL. Reversible reduction of N-acetylaspartate after acute central nervous system damage. In: Proceedings of the Eleventh Annual Meeting of the Society for Magnetic Resonance in Medicine. 1992:643.
22. De Stefano N, Francis G, Antel JP, Arnold DL. Reversible decreases of N-acetylaspartate in the brain of patients with relapsing remitting multiple sclerosis. In: Proceedings of the Twelfth Annual Meeting of the Society for Magnetic Resonance in Medicine. New York: 1993:280.
23. Brenner RE, Beech JS, Williams SCR, Bell JD, McDonald WI. Reversibility of the reduction of NAA in diabetic keto-acidosis. In: Proceedings of the Twelfth Annual Meeting Of the Society for Magnetic Resonance in Medicine. New York: 1993:1559.
24. Crossmann AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
25. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
26. Davie CA, Pirtosek Z, Barker GJ, Kingsley DPE, Miller PH, Lees AJ. Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 1995;58:688-691.